Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.
Rodríguez M, Alonso-Alonso R, Tomás-Roca L, Rodríguez-Pinilla SM, Manso-Alonso R, Cereceda L, Borregón J, Villaescusa T, Córdoba R, Sánchez-Beato M, Fernández-Miranda I, Betancor I, Bárcena C, García JF, Mollejo M, García-Cosio M, Martin-Acosta P, Climent F, Caballero D, de la Fuente L, Mínguez P, Kessler L, Scholz C, Gualberto A, Mondéjar R, Piris MA. Rodríguez M, et al. Among authors: gualberto a. Blood Adv. 2021 Dec 28;5(24):5588-5598. doi: 10.1182/bloodadvances.2021005171. Blood Adv. 2021. PMID: 34592752 Free PMC article.
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
Alonso-Alonso R, Mondéjar R, Martínez N, García-Diaz N, Pérez C, Merino D, Rodríguez M, Esteve-Codina A, Fuste B, Gut M, Burrows F, Scholz C, Vaqué JP, Gualberto A, Piris MÁ. Alonso-Alonso R, et al. Among authors: gualberto a. Sci Rep. 2020 Apr 21;10(1):6721. doi: 10.1038/s41598-020-63434-5. Sci Rep. 2020. PMID: 32317694 Free PMC article.
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. Hanna GJ, et al. Among authors: gualberto a. Cancer. 2020 Sep 1;126(17):3972-3981. doi: 10.1002/cncr.33036. Epub 2020 Jun 18. Cancer. 2020. PMID: 32557577 Free PMC article. Clinical Trial.
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Ho AL, et al. Among authors: gualberto a. J Clin Oncol. 2021 Jun 10;39(17):1856-1864. doi: 10.1200/JCO.20.02903. Epub 2021 Mar 22. J Clin Oncol. 2021. PMID: 33750196 Free PMC article. Clinical Trial.
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Steensma DP, et al. Among authors: gualberto a. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. Leukemia. 2021. PMID: 34172893 Free PMC article. Clinical Trial.
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.
Gilardi M, Wang Z, Proietto M, Chillà A, Calleja-Valera JL, Goto Y, Vanoni M, Janes MR, Mikulski Z, Gualberto A, Molinolo AA, Ferrara N, Gutkind JS, Burrows F. Gilardi M, et al. Among authors: gualberto a. Mol Cancer Ther. 2020 Sep;19(9):1784-1796. doi: 10.1158/1535-7163.MCT-19-0958. Epub 2020 Jul 29. Mol Cancer Ther. 2020. PMID: 32727882 Free PMC article.
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV. Gualberto A, et al. Clin Cancer Res. 2010 Sep 15;16(18):4654-65. doi: 10.1158/1078-0432.CCR-10-0089. Epub 2010 Jul 29. Clin Cancer Res. 2010. PMID: 20670944 Free PMC article. Retracted.
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Haluska P, et al. Among authors: gualberto a. Clin Cancer Res. 2007 Oct 1;13(19):5834-40. doi: 10.1158/1078-0432.CCR-07-1118. Clin Cancer Res. 2007. PMID: 17908976 Clinical Trial.
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.
Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Juergens H, et al. Among authors: gualberto a. J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025154 Free PMC article. Clinical Trial.
79 results